Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Share-based Compensation (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Share-based Compensation for 15 consecutive years, with $25000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 292.31% to $25000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $55518.0 through Dec 2025, up 183.6% year-over-year, with the annual reading at $377000.0 for FY2025, 214.17% up from the prior year.
  • Share-based Compensation hit $25000.0 in Q4 2025 for Guided Therapeutics, up from $15118.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.1 million in Q2 2023 to a low of -$821353.0 in Q4 2022.
  • Historically, Share-based Compensation has averaged $62996.2 across 5 years, with a median of $21091.5 in 2023.
  • Biggest five-year swings in Share-based Compensation: crashed 1742.71% in 2022 and later surged 2443.18% in 2023.
  • Year by year, Share-based Compensation stood at $50000.0 in 2021, then plummeted by 1742.71% to -$821353.0 in 2022, then skyrocketed by 93.43% to -$54000.0 in 2023, then surged by 75.93% to -$13000.0 in 2024, then skyrocketed by 292.31% to $25000.0 in 2025.
  • Business Quant data shows Share-based Compensation for GTHP at $25000.0 in Q4 2025, $15118.0 in Q3 2025, and $15381.0 in Q2 2025.